| 15.64 0 (0%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 19.49 | 1-year : | 21.25 |
| Resists | First : | 16.68 | Second : | 18.2 |
| Pivot price | 16.49 |
|||
| Supports | First : | 14.23 | Second : | 11.84 |
| MAs | MA(5) : | 15.33  |
MA(20) : | 16.34 |
| MA(100) : | 16.33 |
MA(250) : | 14.14 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27 |
D(3) : | 18.2 |
| RSI | RSI(14): 44 | |||
| 52-week | High : | 22.5 | Low : | 8.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRIX ] has closed above bottom band by 29.7%. Bollinger Bands are 85.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.04 - 17.13 | 17.13 - 17.21 |
| Low: | 14.41 - 14.53 | 14.53 - 14.63 |
| Close: | 15.46 - 15.64 | 15.64 - 15.79 |
Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009. This company, which rebranded from Nurix Inc. in October 2018, is dedicated to the identification, advancement, and commercialization of innovative small molecule treatments for various cancers and immune system disorders. Its robust pipeline features several key drug candidates: NX-2127 and NX-5948: Both are orally administered Bruton's tyrosine kinase (BTK) degraders, targeting B-cell malignancies that have relapsed or are resistant to prior therapies. NX-5948 is also being explored for autoimmune conditions. NX-1607: An orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, developed for immuno-oncology applications. NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance the efficacy of adoptive T-cell therapies. DeTIL-0255: Currently undergoing Phase 1 clinical trials for gynecological cancers, including ovarian, endometrial, and cervical cancers. To further its mission, Nurix has forged significant strategic alliances, notably with Gilead Sciences, Inc. for the development of therapies addressing cancer and other challenging diseases, and also with Sanofi S.A.
Tue, 09 Jun 2026
Nurix Therapeutics (NASDAQ:NRIX) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Tue, 09 Jun 2026
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions (NRIX) - Seeking Alpha
Tue, 09 Jun 2026
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Mon, 08 Jun 2026
Nurix Therapeutics (NRIX) Stock Soars 24% on Roche Collaboration Announcement - GuruFocus
Mon, 08 Jun 2026
NRIX Stock Chops Lower As Insider Form 4 Hits Tape - StocksToTrade
Mon, 08 Jun 2026
Nurix Therapeutics Stock Pops on Roche Partnership - Schaeffer's Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 8.24e+007 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 19,200 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.0731e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 479.4 % |
| Return on Equity (ttm) | -31.5 % |
| Qtrly Rev. Growth | 7.178e+007 % |
| Gross Profit (p.s.) | -35.16 |
| Sales Per Share | -32.66 |
| EBITDA (p.s.) | -1.38085e+008 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -260 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.48 |
| Price to Cash Flow | 6.32 |
| Dividend | 0 |
| Forward Dividend | 1.863e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|